Original Research

Published on 02 May 2024

Gastric cancer actionable genomic alterations across diverse populations worldwide and pharmacogenomics strategies based on precision oncology

in Pharmacogenetics and Pharmacogenomics

Gabriela Echeverría-Garcés
María José Ramos-Medina
Rodrigo Vargas
Alejandro Cabrera-Andrade
Adriana Altamirano-Colina
María Paula Freire
Juliana Montalvo-Guerrero
Sebastián Rivera-Orellana
Paulina Echeverría-Espinoza
Luis A. Quiñones

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1373007

Original Research

Published on 01 May 2024

ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer

in Pharmacogenetics and Pharmacogenomics

Michael V. Orman
Varsha Sreekanth
Teemu D. Laajala
Scott D. Cramer
James C. Costello

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1360352

200 views

Original Research

Accepted on 25 Apr 2024

Exploration on the effect of anserine on the alleviation of DVT and its molecular mechanism

in Pharmacogenetics and Pharmacogenomics

Yan Li
Jingping Ge
Yuanyuan Yin
Juan He
Longcheng Shang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1402758

Original Research

Accepted on 24 Apr 2024

Assessing User Perspectives on Clinical Pharmacogenomics Consultation Documentation: A User-Centered Evaluation

in Pharmacogenetics and Pharmacogenomics

Nina Desai
Namratha Ravindra
Bradley Hall
Hana Al Alshaykh
Lauren Kathleen Lemke
Eda Eken
Emily Jayne Cicali
Kristin Wiisanen
Larisa H Cavallari
Khoa Nguyen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1377132

Original Research

Published on 24 Apr 2024

Establishment of a prognostic risk model for osteosarcoma and mechanistic investigation

in Pharmacogenetics and Pharmacogenomics

Hongyuan Jiang
Xuliang Zhao
Jinhui Zang
Ruijiao Wang
Jiake Gao
Jinli Chen
Tengbo Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1399625

166 views

Review

Published on 24 Apr 2024

The pharmacoepigenetic paradigm in cancer treatment

in Pharmacogenetics and Pharmacogenomics

Belén Ocaña-Paredes
Sebastián Rivera-Orellana
David Ramírez-Sánchez
Juliana Montalvo-Guerrero
María Paula Freire
Samantha Espinoza-Ferrao
Adriana Altamirano-Colina
Paulina Echeverría-Espinoza
María José Ramos-Medina
Gabriela Echeverría-Garcés

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1381168

196 views

Original Research

Accepted on 17 Apr 2024

Association between Coenzyme Q 10-related Genetic Polymorphisms and Statin-associated Myotoxicity in Korean Stroke Patients

in Pharmacogenetics and Pharmacogenomics

Yoon-A Park
Yoonkyung Chang
Da Hoon Lee
Jung Sun Kim
Minju Park
Seo-A Choi
Tae-Jin Song
Hye Sun Gwak

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1358567

Original Research

Published on 17 Apr 2024

Identification of pivotal genes and regulatory networks associated with atherosclerotic carotid artery stenosis based on comprehensive bioinformatics analysis and machine learning

in Pharmacogenetics and Pharmacogenomics

Xiaohong Qin
Rui Ding
Haoran Lu
Wenfei Zhang
Shanshan Wei
Baowei Ji
Rongxin Geng
Liquan Wu
Zhibiao Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1364160

205 views

Systematic Review

Accepted on 15 Apr 2024

Meta-analysis of the effects of CYP3A5*3 gene polymorphisms on tacrolimus blood concentration and efficacyeffectiveness in Chinese patients with membranous nephropathy

in Pharmacogenetics and Pharmacogenomics

Xiaona Dai
Lan Chai

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1385322

Original Research

Published on 11 Apr 2024

Do future healthcare professionals advocate for pharmacogenomics? A study on medical and health sciences undergraduate students

in Pharmacogenetics and Pharmacogenomics

Hanan Al-Suhail
Mohammad Omar
Majd Rubaeih
Tamer Mubarak
Margarita-Ioanna Koufaki
Ioannis Kanaris
Favio Mounaged
George P. Patrinos
Maha Saber-Ayad

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1377420

431 views

Original Research

Published on 10 Apr 2024

Exploring the impact of MiR-92a-3p on FOLFOX chemoresistance biomarker genes in colon cancer cell lines

in Pharmacogenetics and Pharmacogenomics

Paula I. Escalante
Luis A. Quiñones
Héctor R. Contreras

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1376638

292 views

Original Research

Accepted on 05 Apr 2024

Pharmacogenetic landscape of pain management variants among Mediterranean populations

in Pharmacogenetics and Pharmacogenomics

JMEL Haifa
Wided BOUKHALFA
Ismail Gouiza
Roua OULED SEGHAIER
Hamza Dallali
Rym KEFI

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1380613

Original Research

Published on 26 Mar 2024

Estimating preferences and willingness to pay for pharmacogenetic testing in populations who are medically underserved: a discrete choice experiment

in Pharmacogenetics and Pharmacogenomics

Brian E. Gawronski
Ramzi G. Salloum
Julio D. Duarte

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1384667

324 views

Systematic Review

Accepted on 22 Mar 2024

Systematic review of drug-drug interactions of delta-9tetrahydrocannabinol, cannabidiol, and Cannabis

in Pharmacogenetics and Pharmacogenomics

Rahul Nachnani
Amy Knehans
Jeffrey Neighbors
Paul T Kocis
Tzuo Lee
Kayla Tegeler
Thomas Trite
Wesley M Raup-Konsavage
Kent E Vrana

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1282831

125 views

Original Research

Published on 22 Mar 2024

Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships

in Pharmacogenetics and Pharmacogenomics

Viktorija Ulanova
Agnija Kivrane
Anda Viksna
Leonora Pahirko
Lauma Freimane
Darja Sadovska
Iveta Ozere
Andra Cirule
Eduards Sevostjanovs
Solveiga Grinberga

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1332752

724 views
1 citation

Original Research

Accepted on 15 Mar 2024

Genetic variation in UGT1A1 is not associated with altered liver biochemical parameters in healthy volunteers participating in bioequivalence trials

in Pharmacogenetics and Pharmacogenomics

Eva González-Iglesias
Dolores Ochoa
Manuel Román
Paula Soria-Chacartegui
Samuel Martín-Vilchez
Marcos Navares-Gómez
Alejandro De Miguel
Pablo Zubiaur
Andrea Rodríguez-Lopez
Francisco Abad-Santos

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1389968

Navigation group

Articles

Gastric cancer actionable genomic alterations across diverse populations worldwide and pharmacogenomics strategies based on precision oncology

ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer

Exploration on the effect of anserine on the alleviation of DVT and its molecular mechanism

Assessing User Perspectives on Clinical Pharmacogenomics Consultation Documentation: A User-Centered Evaluation

Establishment of a prognostic risk model for osteosarcoma and mechanistic investigation

The pharmacoepigenetic paradigm in cancer treatment

Association between Coenzyme Q 10-related Genetic Polymorphisms and Statin-associated Myotoxicity in Korean Stroke Patients

Identification of pivotal genes and regulatory networks associated with atherosclerotic carotid artery stenosis based on comprehensive bioinformatics analysis and machine learning

Meta-analysis of the effects of CYP3A5*3 gene polymorphisms on tacrolimus blood concentration and efficacyeffectiveness in Chinese patients with membranous nephropathy

Do future healthcare professionals advocate for pharmacogenomics? A study on medical and health sciences undergraduate students

Exploring the impact of MiR-92a-3p on FOLFOX chemoresistance biomarker genes in colon cancer cell lines

Pharmacogenetic landscape of pain management variants among Mediterranean populations

Estimating preferences and willingness to pay for pharmacogenetic testing in populations who are medically underserved: a discrete choice experiment

Systematic review of drug-drug interactions of delta-9tetrahydrocannabinol, cannabidiol, and Cannabis

Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships

Genetic variation in UGT1A1 is not associated with altered liver biochemical parameters in healthy volunteers participating in bioequivalence trials